Ever wondered how modern medicine addresses the challenge of drugs that don’t meet required bioavailability effectively? The solution is found in Amorphous Solid Dispersions (ASDs). ASDs have significantly transformed our approach to these drugs, enhancing their effectiveness.
I am delighted having been invited to speak on this fascinating area of pharmaceutical science at the upcoming Formulation Science and Technology Interest Group meeting, organized by the Royal Society of Chemistry in London. This event is set to bring together prominent scientists from both academic and industrial backgrounds who specialize in the field of ASDs. I am particularly excited about this opportunity, as it aligns perfectly with amofor’s focus on in-silico strategies to develop such formulations.
Exploring the World of ASDs
ASDs are a game changer for the formulation of poorly water-soluble drugs, a challenge that affects up to 90 percent of the current molecules in development. These drugs often lack bioavailability in their original crystalline state, making enabling techniques indispensable for successful formulation.
In recent years, the ASD field has seen a significant increase in market presence, with numerous ASD-formulated drugs being introduced. This rise shows that ASDs are no longer the ultima ratio for few molecules, but became a crucial element of modern drug formulation. Originating in the 1970s, ASDs have undergone remarkable development, now capable of addressing complex formulation challenges for a variety of molecules. Today, ASDs allow to formulate a broad range of molecules, including poorly soluble compounds with high or low melting points, and labile molecules that crystallize quickly. This adaptability underscores the broad applicability of ASDs in modern pharmaceuticals.
At the upcoming meeting, we’ll dive into the challenges and innovative solutions that ASDs offer. It will be a fantastic opportunity to discuss manufacturing techniques, analytical methods, and physics-based in-silico modelling for ASDs. Discussions will span a range of topics, from spray drying, and hot melt extrusion to co-precipitation approaches, offering a comprehensive overview of ASDs’ current applications and future potential. In addition, I will present an in-silico GPS to navigate the complex field of drug formulation, with PC-SAFT acting as our compass to predict and improve formulation stability. This method represents a unique alternative to traditional trial-and-error approaches and enables a deeper understanding of formulation behavior. In particular, we will explore how the crystallization onset times can be predicted using this innovative modeling approach. Our commitment to a tailored approach in drug formulation reflects our belief in the necessity of addressing the unique properties of each API molecule individually.
Looking Ahead: The Future of Drug Formulation and Collaboration
The future of drug formulation is facing a transformation, shifting from traditional methods that primarily involve using crystalline materials with added excipients, to personalized and more precise strategies. We are advancing towards a sophisticated toolbox in drug formulation that enables the meticulous design of customized release and stability profiles for each molecule. Achieving this level of precision in formulation requires a deep understanding of the molecules involved and their interactions with various excipients. It involves a thorough characterization of these interactions to facilitate the development of smarter, safer, and more effective treatments that are tailored to meet individual needs.
An Invitation to Meet Us
The meeting represents a fantastic opportunity for learning and I’m particularly looking forward to exploring collaborative opportunities and engaging with leading formulators from the ASD field.
Join us to get an exclusive insight into the latest ASD breakthroughs. Register now, and we look forward to meeting up.
Let’s come together to shape the future of drug formulation!